New diabetes pill put to the test against standard treatment
NCT ID NCT07436182
Summary
This study aims to see if a newer diabetes drug, imeglimin, works better than the standard first-choice drug, metformin, at improving how the body's cells produce energy. It will involve 176 adults newly diagnosed with type 2 diabetes who haven't started any medication yet. Researchers will measure specific blood markers related to cellular energy after 12 weeks of taking one of the two drugs.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METFORMIN are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mansoura university hospitals
Al Mansurah, Province, 31951, Egypt
Conditions
Explore the condition pages connected to this study.